Business Description
Mineralys Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US6031701013
Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -91.3 | |||||
| 3-Year EPS without NRI Growth Rate | -86.1 | |||||
| 3-Year FCF Growth Rate | -108.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.5 | |||||
| 9-Day RSI | 48.56 | |||||
| 14-Day RSI | 45.78 | |||||
| 6-1 Month Momentum % | 59.5 | |||||
| 12-1 Month Momentum % | -0.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.76 | |||||
| Quick Ratio | 23.76 | |||||
| Cash Ratio | 22.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -60.7 | |||||
| Shareholder Yield % | -37.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -34.77 | |||||
| ROA % | -28.96 | |||||
| ROIC % | -576.12 | |||||
| ROC (Joel Greenblatt) % | -3995.14 | |||||
| ROCE % | -35.5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.03 | |||||
| Price-to-Tangible-Book | 2.03 | |||||
| EV-to-EBIT | -6.51 | |||||
| EV-to-Forward-EBIT | -2.55 | |||||
| EV-to-EBITDA | -6.51 | |||||
| EV-to-Forward-EBITDA | -2.56 | |||||
| EV-to-FCF | -6.79 | |||||
| Price-to-Net-Current-Asset-Value | 2.05 | |||||
| Price-to-Net-Cash | 2.16 | |||||
| Earnings Yield (Greenblatt) % | -15.36 | |||||
| FCF Yield % | -13.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLYS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mineralys Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.02 | ||
| Beta | 0 | ||
| Volatility % | 78.55 | ||
| 14-Day RSI | 45.78 | ||
| 14-Day ATR ($) | 0.666633 | ||
| 20-Day SMA ($) | 12.238 | ||
| 12-1 Month Momentum % | -0.16 | ||
| 52-Week Range ($) | 5.85 - 17.7 | ||
| Shares Outstanding (Mil) | 49.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mineralys Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mineralys Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mineralys Therapeutics Inc Frequently Asked Questions
What is Mineralys Therapeutics Inc(MLYS)'s stock price today?
The current price of MLYS is $11.87. The 52 week high of MLYS is $17.70 and 52 week low is $5.85.
When is next earnings date of Mineralys Therapeutics Inc(MLYS)?
The next earnings date of Mineralys Therapeutics Inc(MLYS) is 2024-05-15 Est..
Does Mineralys Therapeutics Inc(MLYS) pay dividends? If so, how much?
Mineralys Therapeutics Inc(MLYS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers